- Home
- KREF vs XERS Comparison
KREF vs XERS Comparison
Compare KREF & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KREF
- XERS
- Stock Information
- Founded
- KREF 2014
- XERS 2005
- Country
- KREF United States
- XERS United States
- Employees
- KREF N/A
- XERS N/A
- Industry
- KREF Real Estate Investment Trusts
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- KREF Real Estate
- XERS Health Care
- Exchange
- KREF Nasdaq
- XERS Nasdaq
- Market Cap
- KREF 623.1M
- XERS 727.1M
- IPO Year
- KREF 2017
- XERS 2018
- Fundamental
- Price
- KREF $8.82
- XERS $4.63
- Analyst Decision
- KREF Buy
- XERS Strong Buy
- Analyst Count
- KREF 8
- XERS 6
- Target Price
- KREF $12.22
- XERS $6.25
- AVG Volume (30 Days)
- KREF 720.4K
- XERS 2.3M
- Earning Date
- KREF 07-21-2025
- XERS 08-07-2025
- Dividend Yield
- KREF 11.46%
- XERS N/A
- EPS Growth
- KREF N/A
- XERS N/A
- EPS
- KREF 0.16
- XERS N/A
- Revenue
- KREF $97,478,000.00
- XERS $222,551,000.00
- Revenue This Year
- KREF $31.59
- XERS $35.03
- Revenue Next Year
- KREF $7.29
- XERS $18.31
- P/E Ratio
- KREF $53.68
- XERS N/A
- Revenue Growth
- KREF 93.07
- XERS 29.88
- 52 Week Low
- KREF $8.28
- XERS $2.03
- 52 Week High
- KREF $12.95
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- KREF 35.23
- XERS 50.34
- Support Level
- KREF $9.03
- XERS $4.59
- Resistance Level
- KREF $9.10
- XERS $4.90
- Average True Range (ATR)
- KREF 0.18
- XERS 0.18
- MACD
- KREF -0.05
- XERS 0.02
- Stochastic Oscillator
- KREF 9.73
- XERS 56.67
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).